Daniel Karlin insider trades: Definium Therapeutics (DFTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Daniel reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | DFTX | ↓ Sell | 10,853 | $36.57 | $397K | Direct | Sep 29, 2026 (4d) |
| Sep 25, 2025 | MNMD | ↓ Sell | 7,704 | $9.77 | $75K | Direct | Sep 26, 2025 (1d) |
| Jun 25, 2025 | MNMD | ↓ Sell | 7,848 | $6.80 | $53K | Direct | Jun 26, 2025 (1d) |
| Mar 25, 2025 | MNMD | ↓ Sell10b5-1 | 6,836 | $6.74 | $46K | Direct | Mar 26, 2025 (1d) |
| Dec 26, 2024 | MNMD | ↓ Sell | 6,643 | $7.43 | $49K | Direct | Dec 27, 2024 (1d) |
| Sep 25, 2024 | MNMD | ↓ Sell | 6,871 | $5.98 | $41K | Direct | Sep 25, 2024 (0d) |
| Jun 25, 2024 | MNMD | ↓ Sell10b5-1 | 6,925 | $7.22 | $50K | Direct | Jun 25, 2024 (0d) |
| Mar 25, 2024 | MNMD | ↓ Sell | 6,578 | $9.50 | $62K | Direct | Mar 26, 2024 (1d) |
| Dec 26, 2023 | MNMD | ↓ Sell | 6,774 | $3.63 | $25K | Direct | Dec 26, 2023 (0d) |
| Sep 25, 2023 | MNMD | ↓ Sell | 6,918 | $3.57 | $25K | Direct | Sep 25, 2023 (0d) |
| Jun 27, 2023 | MNMD | ↓ Sell | 6,783 | $3.20 | $22K | Direct | Jun 27, 2023 (0d) |
| Mar 1, 2023 | MNMD | ↓ Sell | 3,577 | $3.51 | $13K | Direct | Mar 2, 2023 (1d) |
| Dec 21, 2022 | MNMD | ↓ Sell | 1,211 | $2.69 | $3K | Direct | Dec 22, 2022 (1d) |
| Oct 27, 2022 | MNMD | ↓ Sell | 1,185 | $2.91 | $3K | Direct | Oct 27, 2022 (0d) |
| Sep 27, 2022 | MNMD | ↓ Sell | 1,205 | $5.70 | $7K | Direct | Sep 27, 2022 (0d) |
| Aug 31, 2022 | MNMD | ↓ Sell | 1,204 | $11.67 | $14K | Direct | Sep 1, 2022 (1d) |
| Jul 27, 2022 | MNMD | ↓ Sell | 18,217 | $0.69 | $13K | Direct | Jul 27, 2022 (0d) |
| Jun 27, 2022 | MNMD | ↓ Sell | 26,238 | $0.70 | $18K | Direct | Jun 28, 2022 (1d) |
| May 27, 2022 | MNMD | ↓ Sell | 9,555 | $0.82 | $8K | Direct | May 31, 2022 (4d) |
| May 25, 2022 | MNMD | ↓ Sell | 8,242 | $0.77 | $6K | Direct | May 26, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DFTX insiders
Open-market trades in the last 12 months
About Daniel Karlin's insider trades
Daniel Karlin is Chief Medical Officer at Definium Therapeutics (DFTX). Since May 25, 2022, Daniel has reported no open-market purchases and 20 sales worth $931K on SEC Form 4. In the last 12 months: 1 sale ($397K).
2 sales (10% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (8 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DFTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.